Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development

Fatemeh Azizian-Farsani, Navid Abedpoor, Mohammad Hasan Sheikhha, Ali Osmay Gure, Mohammad Hossein Nasr-Esfahani and Kamran Ghaedi

Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, Academic Center for Education, Culture and Research (ACECR), Isfahan, Iran, Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Turkey, Division of Cellular and Molecular Biology, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran

Receptor for advanced glycation end-products (RAGE) is a multiligand binding and single-pass transmembrane protein taken in diverse chronic inflammatory conditions. RAGE behaves as a pattern recognition receptor, which binds and is engaged in the cellular response to a variety of damage-associated molecular pattern molecules, as well as HMGB1, S100 proteins, and AGEs (advanced glycation end-products). The RAGE activation turns out to a formation of numerous intracellular signaling mechanisms, resulting in the progression and prolongation of colorectal carcinoma (CRC). The RAGE expression correlates well with the survival of colon cancer cells. RAGE is involved in the tumorigenesis, which increases and develops well in the stressed tumor microenvironment. In this review, we summarized downstream signaling cascade activated by the multiligand activation of RAGE, as well as RAGE ligands and their sources, clinical studies, and tumor markers related to RAGE particularly in the inflammatory tumor microenvironment in CRC. Furthermore, the role of RAGE signaling pathway in CRC patients with diabetic mellitus is investigated. RAGE has been reported to drive assorted signaling pathways, including activator protein 1, nuclear factor-κB, signal transducer and activator of transcription 3, SMAD family member 4 (Smad4), mitogen-activated protein kinases, mammalian target of rapamycin, phosphoinositide 3-kinases, reticular activating system, Wnt/β-catenin pathway, and Glycogen synthase kinase 3β, and even microRNAs.

Keywords: AGEs, advanced glycation end products, CRC, colorectal cancer, damage-associated molecular pattern molecules (DAMPs), pattern recognition receptor (PRR), RAGE (receptor for advanced glycation end products), tumourogenesis

INTRODUCTION

Around 147,950 persons will be identified with colorectal carcinoma (CRC), and 53,200 will die of it by the year 2020, with 17,930 cases and 3,640 deaths in people younger than 50 years. CRC has a complex and multifactorial etiology, strictly related to environmental and genetic factors, including adenomatous polyposis coli (APC) alteration, long-lasting inflammation, metabolic diseases, and also gut microbiota alteration (1–5).
Genetic and epigenetic abnormalities within multistep procedures known as carcinogenesis progressively transform healthy human cells into highly malignant derivatives. Six alterations in the cell physiology essential for malignant progression include the ability to invade and metastasize, bypassing of apoptosis, independence in growth factors, constant angiogenesis, unlimited replicative potential, and insensitivity to growth-inhibitory signals. Moreover, inflammation context, genomic instability, immune devastation, and reprogramming of energy metabolism are hallmarks of cancer (6, 7). The molecular signaling of CRC development, limited diagnosis, and therapy of this lethal disease remain mainly unclear. In this regard, chronic inflammation is broadly considered as an essential factor underlying CRC development.

The receptor for advanced glycation end-products (RAGE) pathway is seriously involved in the pathologies of different cancers. RAGE was first explored as a cell surface receptor for advanced glycation end-products (AGEs). AGEs was also the first ligand recognized for RAGE. Accumulation of AGEs and the other ligands is related to chronic inflammation; hence, RAGE signaling is regarded as a fundamental pathway in inflammation-related disorders. In this regard, inflammation has been well-recognized to take in CRC initiation and progression. In agreement, many studies showed that RAGE signaling has been involved in colitis-associated colon carcinogenesis. Notably, Heijmans et al. recognized that loss of RAGE in mice model prohibited sporadic progression of intestinal adenomas. Studies using CRC cell lines also discovered that RAGE signaling is strongly related to abundant malignant behavior of CRC cells, including chemoresistance, invasion, and proliferation. These findings proposed that RAGE plays a key role in the connection between inflammation and colon carcinogenesis (Figure 1) (8–11).

RAGE ligands, for example, AGEs, exist in modern diet mostly in fast foods and processed foods. Briefly, AGEs form in foods high in protein and fat, which brown through cooking under high temperatures. Also, exposure to dry high temperature produces more AGEs than cooking in liquid. Thus, grilling, broiling, and frying meats generate more AGEs than boiling. For instance, 15 min of broiling a chicken breast form AGEs five times higher than the same food boiled for 1 h. Cigarette smoking is another source of AGEs. It is known that tobacco curing results in forming AGEs (12). Considerably, a diet high in sugar and fat and highly processed, besides an inactive lifestyle, also results in AGE accumulation which contributes to chronic disease development and complications. It has been shown that cancer-associated cell signaling cascades such as MAPK (mitogen-activated protein kinase) and AKT (protein kinase B) are activated through rises of AGE accumulation pool, leading to aberrant cellular functions. As in breast cancer, a link between estrogens receptor (ER) status and AGE levels was observed in tumor and serum samples (13). Thus, changing the lifestyle would decrease AGE burden to promote healthy aging.

This review was assumed to elucidate recent knowledge of RAGE–ligand interaction, the ligand sources, and related tumor markers, taking out from clinical studies and downstream cascades in the context of inflammation, type 2 diabetes (T2D), and also therapeutic strategies, particularly in CRC, and identification of RAGE signaling pathway. The significant role of RAGE signaling pathway in cancer suggests a brilliant molecular target for CRC treatment, especially antimetastatic therapeutics.

**RAGE**

RAGE is a kind of the immunoglobulin protein family with an immunoglobulin-like receptor structure resembling cell surface molecules (14, 15). Furthermore, different inflammation-related molecules, including HMGB1, S100A/calgranulins, α-amyloid, and AGEs, could activate RAGE (16). The localization of RAGE gene is on chromosome 6, and it is close to the dominant histocompatibility complex class III region in humans and mice. The long RAGE mature is 382-amino-acid residues, composed of five domains including extracellular domains such as V-domain, which attaches to ligands, C1 and C2 domains, a single transmembrane spanning helix, and a short cytosolic region, which is an important domain for successful RAGE signaling. RAGE contains two N-glycosylation sites. One is located inside the V-domain, and another adjacent to the V-domain forming oligomers at the cell surface. RAGE contains two N-glycosylation sites. One is located inside the V-domain, and another adjacent to the V-domain (17–19).

Based on numerous pathological conditions, splicing variants of RAGE have been categorized and named. Moreover, the RAGE gene includes 11 introns/exons that could be spliced into the diverse variants at the DNA level. Indeed, RAGE is classified into three primary isoforms, including Nt-RAGE (N-terminally truncated isoform RAGE_v2), the full-length RAGE, and secreted RAGE, which acts as a “decoy receptor” that might be inhibiting RAGE ligands from interacting with cell surface RAGE and is named sRAGE (secretory C-truncated RAGE) (20).

**Abbreviations:** AdipoR, Adiponectin Receptors; AGEs, Advanced Glycation End-Products; AD, Alzheimer’s Disease; Activating Protein-1 (AP-1); CD28, Cluster of Differentiation 28; CRC, Colorectal Cancer; CTLA4, Cytotoxic T-lymphocyte-Activator of Transcription 3; TCTP, Translationally Controlled Tumor Protein; Smad4, SMAD Family Member 4; TNFR2, Tumor Necrosis Factor Receptor 2; T2D, Type 2 Diabetes; TIMP-1, Tissue Inhibitor of Metalloproteinases 1; TLR4, Toll-Like Receptor 4; TNF-α, Tumor Necrosis Factor-α; NF-κB, Nuclear Factor Kapablosis B; NO, Nitric Oxide; MAPKs, A Mito gen-IGF-1, Insulin-Like Growth Factor-1 (IGF-1); IL-8, Interleukin-8; LHP, Lipid genomic instability, immune devastation, and reprogramming of Extracellular Newly Receptor for Advanced Glycation End-Products; FN3K, angiogenesis, unlimited replicative potential, and insensitivity of Differentiation 28; CRC, Colorectal Cancer; mTOR, Mammalian Target of Rapamycin; MyD88, Myeloid Differentiation Primary Activated Protein Kinase; MCP-1, Monocyte Chemoattractant Protein 1; TNF-β, Tumor Necrosis Factor-β; T2D, Type 2 Diabetes; TIMP-1, Tissue Inhibitor of Metalloproteinases 1; TLR4, Toll-Like Receptor 4; TNF-α, Tumor Necrosis Factor-α; NF-κB, Nuclear Factor Kapablosis B; NO, Nitric Oxide; MAPKs, A Mito gen-IGF-1, Insulin-Like Growth Factor-1 (IGF-1); IL-8, Interleukin-8; LHP, Lipid genomic instability, immune devastation, and reprogramming of Extracellular Newly Receptor for Advanced Glycation End-Products; FN3K, angiogenesis, unlimited replicative potential, and insensitivity of Differentiation 28; CRC, Colorectal Cancer; mTOR, Mammalian Target of Rapamycin; MyD88, Myeloid Differentiation Primary Activated Protein Kinase; MCP-1, Monocyte Chemoattractant Protein 1; miTOR Mammalian Target of Rapamycin; MydD88, Myeloid Differentiation Primary Response 88; NF-kB, Transcription Factor Nuclear Factor-kB; NO, Nitric Oxide; PD, Parkinson’s Disease; P3SK, Phosphoinositide 3-Kinases; RAGE, Advanced Glycation End Products Receptor; Ras, Reticular Activating System; ROS, Reactive Oxygen Species; RE, Radioembolization Therapy; sRNA, Small Interfering RNA; Smad4, Smad Protein Family Member 4; SNPs, Single-Nucleotide Polymorphisms; SP-D, Pulmonary Surfactant-Associated Protein D; STAT3, Signal Transducer and Activator of Transcription 3; TCTP, Translationaly Controlled Tumor Protein; T2D, Type 2 Diabetes; TIMP-1, Tissue Inhibitor of Metalloproteinases 1; TRLR4, Toll-Like Receptor 4; TNF-α, Tumor Necrosis Factor-α; TNFR2, Tumor Necrosis Factor Receptor 2; TSH, Total Thiold; VEGF, Vascular Endothelial Growth Factor.
FIGURE 1 | RAGE signaling promotes CRC. Different RAGE ligands are released from several types of cells and start RAGE activation, which enhances ROS/oxidative stress, inflammation, apoptosis and anti-apoptosis, and angiogenesis and led to proliferation, migration, and invasion of CRC tumor cells.

**Role of RAGE in Normal Physiology and Different Pathologies**

RAGE is expressed in diverse cells, mature or immature, including macrophages, monocytes, endothelial cells, fibroblasts, and smooth muscle cells. As throughout the development stages the RAGE expression level is enhanced, principally in the brain, nevertheless, the expression level of RAGE declined in adult tissues, as the activation of RAGE in fibroblasts...
related to the proliferation and migration of fibroblasts in the tumor microenvironment (21). Moreover, compared to other tissues, high RAGE expression is seen in lungs during embryonic development (22–24). So, it has been proposed that RAGE may show properties limited only to the pulmonary environment owning a number of significant physiological roles comprising modulation of cell spreading, adhesion to ECM parts, proliferation, and migration (25).

Also, the upregulation of RAGE is seen during diverse pathological events, including inflammatory bowel disease (IBD), stroke, sepsis, diabetes, renal disease, Alzheimer disease (AD), heart failure, osteoarthritis, atherosclerosis, peripheral vascular disease, psoriasis, rheumatoid arthritis, Takayasu arteritis, and cancer (17, 21, 26–28).

The interaction of RAGE with its diverse ligands can mediate multiple physiological and pathological functions, including inflammation, oxidative stress, neurodegeneration, maintenance of homeostasis, tumorigenesis, promotion of neurite outgrowth, cell survival, cell migration, and neuronal differentiation (29). Furthermore, in skeletal muscle tissue, RAGE expression is developmentally regulated. RAGE can be detected in immature, nearly mature, and some mature myofibers up to 11 days after birth in rodents, with RAGE expression being restricted to the sarcolemma (30). In this regard, the effect of prolonged RAGE blockade in human subjects is important because RAGE plays vital roles in normal physiology (31). The ligands for RAGE in the central nervous system (CNS) include AGEs, b-amyloid peptides, albumin, and S100B protein. As in AD, AGEs and b-amyloid activate RAGE. Several studies, reviewed by Ramasamy et al. (32), have shown that RAGE-dependent modulation of gene expression and cellular properties is dependent on the binding of different ligands for RAGE, each of which activates distinct downstream signaling pathways and elicits cell type–specific effects (26, 27, 32). So as regards tissue-specific RAGE ligand expression, the roles of RAGE vary in different pathologies, and also therapeutic strategies change, as in breast cancer, S100A7 is a promising target therapy but not in colorectal cancer. Moreover, RAGE expression in all the cancers is increased, but in lung cancer, the expression is decreased (26).

**RAGE in Cancer**

Many studies have shown that RAGE is a member of a gene family related to the invasion-genes. There are a close association between RAGE upregulation and etiology of different cancers, including breast, prostate, lung, esophageal, and colorectal cancer. RAGE–ligand interaction leads to increased proliferation, migration, and metastatic nature of tumor cells (33–39). Moreover, Dahlmann et al. in 2014 and Shimomoto et al. in 2012 have found that in the colon and oral carcinogenesis, the expression of RAGE is increased (40–43). While most of normal tissues express low level of RAGE, it might be enhanced in inflammatory conditions as a cellular response. In line with this, inflammation in the intestinal tract, due to T2D or obesity, leads to amplified adenaoma formation. These results were consistent with the findings of Luo et al. which indicated progression and tumor formation, significantly increased by upregulation of RAGE expression in CRC. Moreover, RAGE expression increased in IBD, which is a CRC risk factor (9, 44–47). Liang and colleagues in 2011 have assumed that the amplified density of microvessel was associated with RAGE expression in colorectal cancer, and they claimed that knockdown of RAGE could be prevented by invasion capacity, whereas cell viability did not significantly affect SW480 cells (48). In contrast, some studies have shown that in normal lung tissue and non-small cell lung carcinoma the expressions of HMGB1 and RAGE are increased. Therefore, there is a negative association between RAGE and disease prognosis. However, RAGE declines the malignant phenotypes of the disease, which is associated with differentiation rhabdomyosarcoma and myogenic of myoblasts. In addition, RAGE expression is increased in esophageal cancer. These findings show that the role of RAGE depends on the tissues that are involved and the types of cells (49–53).

Ligand–RAGE is related in a paracrine and autocrine manner in the tumor microenvironment to stimulate cell migration, survival, and invasion (54). Clinical studies have indicated that RAGE is associated with its protumoral property. Moreover, RAGE is relocated to the cytoplasmic membrane during progression from colonic adenoma to colonic adenocarcinoma. In contrast, Kostova et al. in 2010 have found that high-grade cancer could show non-specific RAGE localization (42, 55).

RAGE–ligand (ligand secreted from tumor cells or by nearby tissues) interaction happens in the extracellular tumor microenvironment. While the RAGE expression is high in a tumor, high endogenous ligand expression is not essential for activation of the receptor (56).

Furthermore, Gly82Ser, which is the single-nucleotide polymorphism (SNP) of RAGE (rs2070600), enhances ligand binding to boost the downstream signaling pathway, which is associated with amplified risk of numerous cancer types; particularly, the frequency of this polymorphism is much higher in late-stage CRC patients (57, 58). Thus, polymorphism of RAGE can affect its function.

**LIGANDS**

**Advanced Glycation End-Products**

AGEs are crosslinking compounds formed through non-enzymatic glycosylation between reducing sugars and free amino groups of lipids, proteins, and nucleic acids. Likewise, AGEs have two kinds of forms: endogenous and exogenous (59). To date, well-identified AGEs comprise six subtypes, such as glucose-derived AGEs (AGE-1), glyoxal-derived AGEs (AGE-2), glycolaldehyde-derived AGEs (AGE-3), methylglyoxal (MG)–derived AGEs (AGE-4), glyoxal-derived AGEs (AGE-5), and 3-deoxyglucosone-derived AGEs (AGE-6) (60). Foods are the other source of AGEs (e.g., fast foods, meat, bread, daily products), and their formation is induced by food processing at high temperature, besides different ways such as food store for a long time or additive usage, which amplifies AGEs in the foods (61). Interestingly, the other rich source of AGEs is cigarettes. Jiao and colleagues in 2011 have shown that the plasma level of sRAGE in Finnish male smokers significantly diminished (62).

Many studies have demonstrated AGEs are considered as potent toxic molecules that produce several non-communicable
diseases such as T2D, CRC, cardiovascular diseases, Parkinson disease, AD (63–68). Epidemiological evidence has reported that elevated AGEs were associated with CRC (69).

Interestingly, Shimomoto et al. reported that in Western diet–fed rats [15% linoleic acid (LA) diet with 10% glucose drink], significantly aberrant crypt foci (ACFs) were boosted. In line with this, in another study, it has been shown that AGEs might develop CRC in rats that consumed Western diet (41).

The primary mechanism by which AGEs provoke biological function is through binding to RAGE, which triggers activation of adverse cellular effects contributing to enhancing oxidative stress, inflammation, and tumorigenesis. AGEs or different kinds of ligands bind to sRAGE as acting “receptor decoy” that could inhibit RAGE signaling pathways. Studies have shown that AGEs accumulate in the extracellular of different tissue due to promotion of chronic disease (70, 71).

Moreover, intensive studies have indicated that subtypes of AGEs induced the metastasis and invasion in patients with CRC. Deng and colleagues in 2017 have found that glucose-derivived AGEs, which is a critical subtype of forms of AGEs, induced the metastasis and invasion in patients with CRC (72). Moreover, another subtype of AGEs is glyceraldehyde-derived AGEs that are mediated proinflammatory and pro-oxidative in CRC. Nevertheless, there is controversy in the results; for example, Kong et al. in 2015 have evaluated that glyceraldehyde-derived AGEs were increased in CRC patients, but not in association with colon cancer. Indeed, Kong et al. claimed there is close association with the risk of rectal cancer (69). In agreement with these data, Liang et al. demonstrated RAGE could be associated with increasing microvessel density, invasion capacity, cell viability, and angiogenesis, and knockdown of RAGE repressed expression of vascular endothelial growth factor (VEGF) and SP1 protein in colorectal cancer cells (48).

Likewise, Wang et al. have indicated AGEs might upregulate oncogenes (73).

Another component involved in AGE formation is MG. This compound is produced during glycolysis as a side product. A study by Chiavarina et al. predicted that MG accumulated through higher glucose metabolic rates in tumors (74). Furthermore, Lin et al. in 2018 found that MG had a crucial role in colon cancer progression. Additionally, MG could mediate low-grade carbonyl stress and lead to oxidative stress and inflammation and promote tumor growth, and the degree of malignancy of tumor cells is enhanced (75). On the other hand, exogenous AGEs might increase the amount of glycoxyls, which impair many metabolic processes, especially, cancer development. Sakellariou et al. have assumed AGEs/RAGE increased detoxification enzyme glyoxalase (GLO), and there was a relationship between exogenous AGEs and glycoxyls in CRC patients (76).

**HMGB1**

**HMGB1** gene encodes HMGB1/amphoterin, a non-histone chromosomal structural protein (77). HMGB1 is isolated as a 30-kDa cytosolic heparin-binding protein in growing brain tissue and is related to outgrowth neurite. HMGB1 has diverse functions in the cytoplasm, extracellular milieu, and nucleus. Moreover, HMGB1 binds to a type of non-B DNA type in the nucleus and contributing to several procedures, including recombination, replication, transcription, stability of genomic, and DNA repair (78). Furthermore, in the cytoplasm, HMGB1 is related to motility of cell as noticed in outgrowing neurites. Moreover, HMGB1 in motile cell accelerates the formation of adhesion molecules, actin–polymer formation, and filopodia, in addition to detachment from the extracellular matrix. Fages et al. have shown that the mechanism of HMGB1 is similar to that of outgrowing neurites on cell migration in cancer cells (79). HMGB1 expression is high in immature cells and malignant cells and has the main role of regulating of cell migration function (80).

HMGB1 has different molecular roles in cancer. HMGB1 promotes the expression of cellular inhibitor of apoptosis-2, a target gene of activated nuclear factor-κB (NF-κB), and restricted activation of apoptosomal caspase-9. As result, based on these data, HMGB1 might play an antiapoptotic role in colon cancer and decrease anticancer immune responses by stimulated apoptosis in immune cells (81). Notably, Tang et al. in 2010 have indicated endogenous HMGB1 activates an autophagy signal, which promotes cell survival (82). Interestingly, HMGB1 also has a cytokine function that has an extranuclear role when it is inactively released from necrotic and tumor cells after radiotherapy and chemotherapy or actively from monocytes and macrophages into the extracellular environment (83). HMGB1 expression and secretion are unregulated in response to the stimulation of cells by endotoxin, proinflammatory cytokines, platelet activators, and oxidative stresses in macrophages. These results have supported a paracrine/autocrine mechanism for the amphoterin/RAGE action detected in CRC cells (80, 84).

Moreover, DiNorcia et al. in 2010 and Heijmans et al. in 2012 have demonstrated the prompt of Lin cytokines; cellular stresses and growth factors involving deoxyncholic acid and AGEs could amplify expression of HMGB1 in colon adenomas and carcinomas. In addition, studies have shown that upregulation of HMGB1 and RAGE has been linked with poor prognosis, metastasis, and tumor invasion in colorectal cancer. Based on intensive evidence, the main receptors of HMGB1 could be RAGE and toll-like receptors (TLR)-2 and TLR-4. In line with this, Harada and colleagues in 2007 have found that a specific receptor of HMGB1 was RAGE, and complex of HMGB1/RAGE could mediate abundant biological responses, including angiogenesis, axonal sprouting promotion, and outgrowing neurite and immune cell recruitment to an inflammatory place. Thus, it would be interesting to know which pathways of RAGE are activated by HMGB1 in colorectal cancer (45, 85–88).

Furthermore, in multiple ways, HMGB1 could be modified posttranslationally, which might determine the secretion and location of HMGB1 and bind to proteins and DNA. The difference in bioactivities of HMGB1 might be related to tissue sources or different cell types or its responses to different stimuli (89, 90).

**S100 Family**

S100 is a member of proteins with low molecular weight (9–13 kDa), which is expressed in vertebrates, including at
least 25 relatively non-ubiquitous calcium-binding proteins. Their functions depend on calcium concentration and could be changed. Besides, several studies focused on S100 proteins functions including, at the intracellular level, regulation of cell cycle, motility, differentiation, proliferation, apoptosis, Ca\(^{2+}\) homeostasis, cellular signaling, and energy metabolism. In addition, S100 has another role that regulated a variety of intracellular actions, such as cytoskeletal function, protein phosphorylation, and defense from oxidative cell injury. Interestingly, S100 proteins could be active via surface receptors in paracrine and autocrine manner at the extracellular level. As a result, S100 could be able to activate signaling pathways at these sites of chronic inflammation via peripheral blood mononuclear cells and macrophages, including T lymphocytes and RAGE endothelial cells. Diverse S100 proteins have been documented and have expression in different tissues such as various peripheral tissues in a cell-specific manner. S100 proteins remained in their free form at low calcium state and bind calcium and undergo a specific conformational change after the inflow of calcium through voltage-gated or receptor-induced channels, which results to an adjustment of their hydrophobic surface properties. Furthermore, calcium level elevation led to structure change of S100 proteins; consequently, changing structure could allow interacting with the hydrophobic regions of the target proteins (91–97).

Severe vibrant evidence has shown S100 is involved in a variety of biological events associated with carcinogenesis, such as a gene being located on human chromosome 1q21, which is an area susceptible to genomic rearrangements; altered expression in many malignant disorders; and interaction with numerous proteins, which in carcinogenesis play a vital role. Also, S100 protein might affect target proteins such as p53, NF-κB, and β-catenin (98).

S100 family is regulated by epigenetic mechanisms. Lindsey et al. showed that curing the various medulloblastoma cell lines with DNA demethylation releases S100A3, S100A10, S100I1, and S100P proteins (99). Also, micro-RNAs (mi-RNAs) regulate S100 protein expression; however, there are limited studies in this area, and more investigation is required for this to be elucidated. MiR-568 regulates the expression of NFA53, a transcription factor that triggers S100A4 expression (100, 101). Moreover, it has been reported that S100A6 overexpression is induced after DNA hypomethylation in gastric cancer. Binding of acetylated histone H3 to a promoter in gastric cancer tissue has been seen when there are minor intensities of CpG methylation in the second exon and first intron of the S100A6 gene (102). Also, lower methylation of S100P gene promoter was seen in different prostate cancer cell lines (103).

**S100A8/A9**

Both S100A8 and S100A9 are recognized as calgranulins MRP8 and MRP14 or A and B. S100A8/A9 functions as a heterodimer and has a concurrent expression, whereas the proteins are produced from distinct genes (104, 105). S100A8/A9 is expressed in various cells of myeloid lineage, containing monocytes, granulocytes, early-stage macrophages, neutrophils, myeloid-derived suppressor cells (MDSCs), cancer cells, and neutrophils. S100A8/A9 could be able to activate signaling pathways such as endothelial adhesion of monocytes and neutrophils and chemotaxis for neutrophils and also can serve as a marker of inflammation (93, 111). Additionally, neutrophils are released chemotactants as inflammation, which is induced by extra involvement of inflammatory cells to damage the tissue (112). S100A8 and S100A9 are expressed in initially recruited monocytes; as they mature, they sustain S100A9 and lose S100A8 expression (113). In one study, the expression of HMGB1 and S100A8 significantly was increased but not S100A9 in polyps compared with normal tissue (45). Calprotectin has been involved in a wide range of chronic inflammation complications such as rheumatoid arthritis, cystic fibrosis, transplant rejection, and tuberculosis (114) and likewise multiple sclerosis, IBD, and psoriasis (112, 115, 116). Indeed, calprotectin is common to consider as a biomarker. Moreover, calprotectin fecal levels are commonly measured to identify IBD.

Some investigations indicate S100A8/A9 upregulation in cancer. This inflammatory context promotes tumorigenesis, metastasis by mediating the tumor cells, and migration of monocytes to metastatic sites. Besides, expression of S100A8/A9 in endothelial cells and myeloid in premetastatic organs in response to transforming growth factor β, tumor necrosis factor α (TNFα), and VEGF expressed by distal primary tumors promotes homing of tumor cells to premetastatic niches (11, 117, 118). Growing studies have verified that heterocomplex of S100A8/S100A9 led to MDSC migration and mediated tumor cell invasion (119, 120). Elevated MDSCs and S100A9 were indicated in peripheral blood and tumor tissue from CRC patients. Circulation of MDSCs and S100A9 was positively related to each other and associated with neoplastic progression. Moreover, S100A9 induces and activates chemotaxis; however, it did not affect MDSC viability. On the other hand, S100A9 is involved in immunosuppression during CRC progression by regulating MDSCs. S100A8/A9–RAGE interaction has been revealed to stimulate MDSC migration and tumor growth (104, 119, 121, 122). Ghavami et al. in 2008 claimed that the influence of calprotectin was dependent on the concentration in tumor cells. Ghavami et al. have indicated increased S100A8/9 concentrations enhance the apoptosis in colon carcinoma cell lines. However, tumor cell growth and migration are stimulated in low concentrations (104, 109). Turovskaya et al. showed that risk of colorectal cancer in patients with IBD is amplified. Myeloid progenitors infiltrate into dysplasia sites in human adenoma and colon tumor tissue and secrete S100A8 and S100A9. The primary receptor of S100A8/A9 on the tumor cells is RAGE. Calprotectin might be bound to RAGE and activate NF-κB signaling pathway, which plays a pivotal role in colitis-associated carcinoma (11).

**S100A4**

S100A4 (metastatin-1, calvasculin) is a multifunctional protein with localization in the extracellular space, cytoplasm, and nucleus. The S100A4 expression was highly in diverse cancer
tissues, related to metastatic tumor development, particularly in CRC patients. Intensive evidence shows that the expression of S100A4 could be considered as a prognostic marker in CRC. Different studies have shown that expression of S100A4 in CRC-xenografted mice is associated with metastases progression. Likewise, increasing expression of S100A4 is often related to pathological disorders including metastasis formation, epithelial–mesenchymal transition (EMT), and tumor outgrowth (47, 123–129).

S100A4 drives metastasis formation in different ways. Interestingly, the motility of cancer cells could be mediated by intracellular interactions with tumor-suppressing proteins, as well as components of the cytoskeleton. Besides, the intracellular S100A4 might increase cell motility through interactions with the proteins of cytoskeleton, including non-muscle tropomyosin, non-muscle myosin II, and actin filaments. Additionally, liprin β1 interacts with metastatin-1 and promotes invasiveness of primary tumors, which leads to cell adhesion causing a migratory phenotype. Besides, S100A4 bound to p53, which increased the progression of a more aggressive cell phenotype and ended in a modulation of p53 transcriptional function. Moreover, S100A4 recruits the factors of the immune system, or remodeling the extracellular matrix in the tumor–stroma microenvironment aggravates metastasis formation. S100A4 is released into extracellular space and stimulates endothelial cell motility and interacts with annexin II on the surface of endothelial cells, which enables angiogenesis and activates matrix metalloproteinase expression, which cleaves proteins of the extracellular matrix and thereby facilitates cell invasion into the adjacent tissues (93, 130–136).

**S100P**

S100P was first purified in 1992 as a 95-amino-acid protein from human placenta, with a partial cellular spreading (137). It has been confirmed that elevated expression of S100P and then interaction with RAGE induce metastases, cell proliferation, and tumor invasion, like in colon cancer. Indeed, evidence has indicated S100P is among three signature genes that induce liver metastasis in a mouse model of colorectal cancer. In contrast, suppression of S100P inhibited colon cancer metastasis and growth, although ameliorated mice survival (8, 138, 139). Research has shown that S100P is augmented in inflammatory disorders such as IBD (8). Prostaglandin E2, which is augmented in epithelial CRC cells, could unregulate S100P. Notably, the S100P protein expression was related to the localization of the primary CRC tumor: the levels of S100P expression were elevated from the right to the left, being the maximum in the rectal carcinomas. Kaplan–Meier has investigation shown that elevated expression of S100P led to decrease of survival time of patients with CRC stages I, II, and III. These results have revealed there was a correlation between expression protein of S100P and survival time (140, 141).

**CLINICAL STUDIES**

Table 1 summarizes clinical studies in CRC patients. It is well-recognized that CRC screening and monitoring strategies such as diagnosis and elimination of premalignant lesions and adenosomatous polyps result in reduction of CRC mortality (157). Several clinical studies have pursued to carry out biomarkers that could be identified as potent metastasis diagnosis in patients with colorectal cancer. Kuniiyasu et al. in 2003 have investigated 119 non-diabetic patients with CRC, who found out RAGE expression was increased in 55% of the cases. Besides, Sasahira et al. have investigated 96 colorectal adenomas and demonstrated that RAGE expression was significantly increased in adenomas with severe atypia, especially with membranous pattern (55, 150, 158). Likewise, Liu and colleagues in 2014 studied the cases of 21 colorectal cancer patients with metabolic syndrome. They assessed circulating interleukin-6 (IL-6), VEGF, fasting insulin, and tumor expression of insulin-like growth factor-1 receptor (IGF-1R), insulin receptor (IR), insulin-like growth factor-1 (IGF-1), and RAGE markers before surgery and 6 months after tumor surgery. Liu et al. have indicated no differences in some circulating cytokines such as IL-6, IGF-1, and VEGF-1 in patients with CRC. However, Liu et al. observed RAGE and IGF-1 expressions were as biomarker in tumor tissue. Furthermore, hyperinsulinemia might be associated with metabolic syndrome and colon cancer (151). Additionally, Tóth et al. in 2007 considered four SNPs such as TNFα−308 G > A, RAGE−429 T > C, HSP70-2−1267 A > G, and LTA 252 A > G in genomic DNA in 183 Hungarian patients with CRC, and they observed that RAGE−429C, TNFα−308A, HSP70-2−1267G, and LTA 252G (8.1AH) haplotype were more frequent (19.1%) in patients with CRC (155).

Another biomarker that clinical studies focused on was sRAGE. According to evidence, some studies have indicated sRAGE was diminished in CRC. Chen et al. in 2016 have demonstrated that sRAGE was inversely correlated with body mass index (BMI). Also, among women with BMI ≥25 kg/m², risk of CRC with the highest sRAGE concentration was significantly lesser compared to women with lower sRAGE concentration. On the other hand, the RAGE pathway might be a pivotal key in CRC with obesity in postmenopausal women (143). In another study, Choi and colleagues have examined the association between biomarkers and respiratory complications in 46 patients with CRC. This study has predicted that plasma sRAGE and S100A12 could be an appropriate biomarker for diagnosing the development of postoperative respiratory complications (144). Notably, Jiao et al. have studied the cases of 29,133 Finnish male smokers and found that increasing levels of serum sRAGE were associated with decreasing risk of CRC in male smokers (62). Also, Jiao et al. in 2012 observed plasma levels of sTNF-αRII, sTNF-αRI, TNFβ, IFNα2, sIL-6R, MCP1, epidermal growth factor (EGF), granulocyte colony-stimulating factor (G-CSF), and VEGF significantly increased; in addition, sRAGE level was decreased in 158 cases with colorectal adenoma (148). Furthermore, Comstock et al. in 2014 have found that serum concentrations of VEGF and C-peptide were amplified in 126 asymptomatic men (48-65 years old), and sRAGE was decreased but did not associate IGF-1 with polyp number or type. They assumed these biomarkers could benefit the diagnosis more than colonoscopy (145).

In contrast, Kong et al. assumed that elevated levels of glycer-AGEs were not significantly associated with colon cancer risk but had a positive association with the risk of rectal cancer (69).
Interestingly, Hamaguchi and colleagues in 2019 have explored eight biomarkers that were associated with potential prognosis in 62 metastatic CRC patients who received aflibercept plus FOLFIRI. Consequently, they claimed tissue tenasin-C, IL-8, extracellular new receptor for advanced glycation end-products (EN-RAGE), pulmonary surfactant–associated protein D, tissue inhibitor of metalloproteinases 1 (TIMP-1), kallikrein 5, tumor necrosis factor receptor 2 (TNFR2), and IGF-binding protein 1 were identified as biomarkers potentially prognostic for overall survival. In addition, among these biomarkers, the lower the levels of TIMP-1, IL-8, and EN-RAGE \((P < 0.001)\), the more overall survival was indicated \((1.47)\). Fahmueller et al. in 2013 investigated a homogenous cohort of CRC patients with hepatic metastases and showed that after 24 h radioembolization (RE) therapy the serum levels of HMGB1 were enhanced, whereas RAGE and DNase levels remained unchanged. So, HMGB1 is a valuable serum biomarker for early estimation of therapy response and prognosis in CRC patients with liver metastases undertaking RE therapy \((146)\). Moreover, glucose promotes Millard reaction and develops adverse effects on exposed cells. In this regard, fructosamine 3 kinase \((FN3K)\) enzyme was recognized as a repair protein in human tissues. Interestingly, Caruso et al. have found that 31 CRC patients had deficient FN3K gene expression, which resulted in significant detrimental effects of “sugar stress” on cell function in 31 CRC patients \((142)\). Royse et al. indicated lower expression of AGER, IL1A, MYD88, and TLR5; however CXCL8 and S100P were higher in tumor epithelia, which was correlated with less survival \((152)\).

Intensive researches have been made over the past decades to give insight into the relationship between reactive oxygen species \((ROS)\) and CRC \((159–161)\). Consistently, Zinkzuk et al. in 2019 carried out a study and showed superoxide dismutase was amplified, whereas the activities of catalase, glutathione peroxidase, and glutathione reductase were lower in 50 CRC patients. Zinkzuk et al. have assumed redox could be potential biomarkers for CRC diagnosis \((156)\). Moreover, Sakellariou et al. confirmed that detoxification enzyme GLO-I expression was directly related to RAGE, but inversely related to AGEs in 133 primary CRC cases. In addition, they found that RAGE and adiponectin receptors \((AdipoR1)\) could be involved in CRC, which concluded that AdipoR2 and GLO-I appeared as novel independent prognostic biomarkers for patients at early disease stage \((76)\).

### Molecular Mechanisms

As already mentioned, cancer cells, dying cancer cells after chemotherapy, express and release RAGE ligands, or AGE intake via diet can act in an autocrine and paracrine manner at tumor–host interface. According to Table 2, which includes studies on involvement of RAGE signaling pathways in colorectal cancer tumorigenesis, tumor growth, migration, and invasion, RAGE has been reported to drive assorted signaling pathways, including activation of activator protein 1 \((AP-1)\), NF-κB, signal transducer and activator of transcription 3 \((STAT3)\), SMAD family member 4 \((Smad4)\), MAPKs, mammalian target of rapamycin \((mTOR)\), phosphoinositide 3-kinases \((PI3K)\), reticular-activating system \((Ras)\), Wnt/β-catenin pathway, and glycogen synthase kinase 3β \((GSK3β)\), and even microRNAs \((Figure 2)\). However, most of these pathways were stimulated by different upstream kinase

### Table 1 | Tumor marker expression in tumor tissue and plasma of CRC patients related to RAGE signaling pathway.

| References                        | CRC patients/samples | Biomarker                      |
|-----------------------------------|----------------------|--------------------------------|
| Caruso et al. \((142)\)           | 31                   | FN3K                           |
| Chen et al. \((143)\)             | 1,249                | sRAGE                          |
| Chiavarina et al. \((74)\)        | 102 \((Tumors)\)     | MG, GLO-I                      |
| Choi et al. \((144)\)             | 46 \((Plasma)\)      | sRAGE and S100A12              |
| Comstock et al. \((145)\)         | 126 \((Serum)\)      | VEGF,C-peptide, sRAGE          |
| Deng et al. \((72)\)              | 160 \((Tumors and serum)\) | Glucose-derived AGEs, RAGE, SP1 and MMP2 |
| Fahmueller et al. \((146)\)       | 49 \((Serum)\)       | HMGB1                          |
| Haraguchi et al. \((147)\)        | 62                   | TIMP-1, IL-8, and EN-RAGE \((more overall survival)\) |
| Harada et al. \((86)\)            | 50 \((Tumor tissues)\) | Trophinin                      |
| Huang et al. \((88)\)             | 30 \((Tissue and serum)\) | TCTR, HMGB1                    |
| Huang et al. \((88)\)             | 106                  | phospho-Drp1Ser616,RAGE 106G25 polymorphism \((rs2070600)\) |
| Huang et al. \((121)\)            | 52 \((China; tumor tissue and blood)\) | S100A9 and MDSCs               |
| Jiao et al. \((62)\)              | 29,133 \((Finnish male smokers; serum)\) | sRAGE                          |
| Jiao et al. \((148)\)             | 158 \((plasma)\)     | sTNF-αRI, sTNF-αRII, sIL-6R, EGF, IFNα2, G-CSF, MCP1, TNFα, VEGF, and decreased sRAGE |
| Kong et al. \((69)\)              | 396 \((Rectal cancer, serum)\) | Glycer-AGE                     |
| Kucukhuseyin et al. \((149)\)     | 80 \((Istanbul)\)    | AGEs                           |
| Kuniyasu et al. \((150)\)        | 119 \((Non-diabetic)\) | Coexpression of RAGE and amphoterin |
| Liu et al. \((151)\)              | 21 \((10 MS, 11 non-MS)\) | IGF-1R, RAGE, IR              |
| Qian et al. \((58)\)              | 90                   | RAGE gene Gly82Ser polymorphism |
| Royse et al. \((152)\)            | 65 \((Males; tumor epithelia)\) | AGER, IL1A, IL6, MyD88, and TLR5 |
| Sakellariou et al. \((76)\)       | 133 \((Colonic mucosa)\) | AGE, RAGE and GLO-I, AdipoR2    |
| Sasahira et al. \((55)\)          | 96                   | Membranous RAGE expression     |
| Shen et al. \((153)\)             | 90 \((Tissue)\)      | SOX9 and S100P                 |
| Shen et al. \((154)\)             | 25                   | S100P                          |
| Tóth et al. \((155)\)             | 183 \((Hungarian)\)  | TNF-a-2308A, RAGE 2429C, HSP70-2 21267G, LTA 252G \((8.1AH)\) haplotype |
| Turovskaya et al. \((11)\)        | 9 \((Tumor tissues)\) | Carboxylated glycans, RAGE, and S100A8/A9 |
| Zinkzuk et al. \((156)\)          | 50                   | Catalase and malondialdehyde   |
TABLE 2 | Basic studies revealed the molecular mechanism involved in RAGE signaling pathway in CRC.

| References          | Tissue/cell lines/animal model               | Ligands              | RAGE molecular mechanism                      |
|---------------------|---------------------------------------------|----------------------|-----------------------------------------------|
| Ang et al. (108)    | SW837, SW480, Pan c-1/SWD20, SWK3          | S100A8/A9            | Smad4                                         |
| Dahlanmann et al. (40) |                                             | S100A4               | MAPK/ERK and hypoxia                          |
| Deng et al. (72)    | 160 Tumors/SW1116, SW480, SW620, HCT116, Caco2, HT29, LoVo | AGEs-BSA             | RAGE/ERK/SP1/MMP2                            |
| Fuentes et al. (8)  | Caco-2 and SW480                            | S100P                | ERK and NF-κB                                 |
| Huang et al. (88)   | 30 Tumors/LoVo cells/małe BALB/c nude mice (Liver metastasis model) xenograft tumor model | HMGB1                | NF-κB                                         |
| Huang et al. (88)   | SW480, SW620, LoVo, and LoVoOXR/tumor tissue | HMGB1                | ERK1/2/Drp1                                   |
| Huang et al. (121)  | LoVo-induced MDSCs model/52 whole blood samples of CRC patients | S100A9               | RAGE-p38 MAPK and TLR4-NF-κB                  |
| Ichikawa et al. (109)| Mice colitis-associated colon cancer/MC38 cells | S100A8/A9            | MAPK and NF-κB                                 |
| Kuniyasu et al. (158)| Rat peritoneal and human alveolar macrophages, WiDr, and PMA-U937 cells | HMGB1/ampihoterin    | Rac1 and JNK/SAPK                              |
| Kuniyasu et al. (162)| Colo320, DLD1, WiDr, and TCO cells         | (AGE-BSA/ampihoterin | ERK-1/2, Rac1 and AKT/MMP9, and NF-κB/65/NO   |
| Liang et al. (48)   | SW480, HCT116, SW620, LOVO, and Colo205 cell lines/45 CRC tissue samples | —                   | SP1/VEGF                                      |
| Mercado-Pimentel et al. (163)| SW480 and LS174T                      | S100P                | AP-1/miR-21/RECK                              |
| Onyeagucha et al. (164)| DLD-1, HEK-293T, LS174T, and SW480 cell lines | S100P                | AP-1/miR-155                                  |
| Qian et al. (165)   | HCT116 and SW480 CRC cells                 | HMGB1                | K-Ras/Yap1                                    |
| Sack et al. (127)   | HCT116 (HAB-88 and HAB-92)/xenograft mice | S100A4               | Wnt/b-catenin                                  |
| Sharma et al. (166) | HT-29, MCF-7, and A549                      | HMGB1                | TLR4/MAPK and P3K                              |
| Shen et al. (153)   | CRC tissue samples/HCT 116/tumorigenesis mice model | S100P                | SOX9/S100P                                    |
| Shen et al. (154)   | 25 CRC tissue samples/LS174T and HCT116 cells/tumorigenesis mice model | S100P                | MAPK/ERK                                      |
| Turovskaya et al. (11)| 9 Tumor tissue samples/RAGE−/−, RAGE+/+ CS7BL/6 mice/CAC mice model (AOM/DSS)/HT-29, Caco-2 and CT-26 | S100A8/A9            | TLR4, glycans, and RAGE                       |
| Wang et al. (73)    | HCT116/diabetic mouse model [ICR mice/streptozotocin (STZ)] | AGES                 | KLF5/MDM2/pS3 and Rb                          |

HMGB1

HMGB1–RAGE interaction at tumor cells acts through different molecular pathways, leading to tumor proliferation, migration, and invasion. It has been shown that RAGE knockdown mice developed decreased tumor number, size, and histopathologic grade. However, gain of function of RAGE and following HMGB1–RAGE interaction led to development of more intestinal adenomas and also increased the hepatic tumor loads. In this context, RAGE blocking by sRAGE or genetic deletion of RAGE (Rage−/−) reduced hepatic tumor rate, nodules, and load (87). In parallel, ApcMin−/−/MyD88−/− mice showed similar phenotype proposing that RAGE and MyD88 signaling share tumor-promoting mechanisms (45, 167).

Moreover, some protein overexpression has a positive effect on HMGB1 overexpression and translocation to cytoplasm and extracellular matrix of tumor cells, making an inflammation context microenvironment. Much evidence reveals that transationally controlled tumor protein (TCTP), a very conserved and multifunctional protein, is involved in the tumorigenesis of several malignances (168). TCTP level in colon tumor tissues and HMGB1 level in serum of CRC patients were significantly increased. In line with this, TCTP overexpression on colon cancer cell lines resulted in the release of HMGB1 from the nucleus to the cytoplasm and into the extracellular space led to activation of NF-κB through the RAGE/TLR4/HMGB1 pathway, which simplified CRC cell invasion. This process is inverted by inhibition of the HMGB1-TRIF/NF-κB pathway by specific antibodies significantly inhibiting the invasion (Figure 3A) (88). However, it has been shown that the NF-κB level in PMAU937 cells treated with HMGB1 was not considerably different from that in untreated cells. PMAU937 cells were high in phosphorylated levels of Rac1/Cdc42 and JNK/SAPK result in proapoptotic consequence. Moreover, high NF-κB activation generates a survival signal to cells via antiapoptotic effect. The result depends on balancing of proapoptotic and antiapoptotic signals and other stimulating growth factors and cytokines. Also, they showed that HMGB1 is not a strong stimulant of nitric oxide (NO) in macrophages and so could not prompt cell death by NO (Figure 3B) (158). Glucose deprivation in tumor microenvironment is another...
FIGURE 2 | RAGE signaling pathway. The receptor of advanced glycation end-products (RAGE) is associated to triggering proinflammatory intracellular signaling cascades once it is engaged by RAGE ligands, leading to consistent and robust cellular responses. Once engaged, multiple signaling pathways are triggering.

(Continued)
stimulant of HMGB1 strong release of HMGB1 from several types of cancer cell lines under normal oxygen concentration, leading to activation of RAGE and TLR4, causing the activation of the MAPK/MEK1/2 and PI3K signaling pathways, leading to colonic myofibroblast migration and invasion (166). However, it has been indicated that, in the normal glucose state in NCM460 cells, proliferation is augmented by overexpression of HMGB1. Under a high glucose state, HMGB1 expression is elevated and released from cell nuclei into the cytoplasm and extracellular matrix of tumor (169) (Figure 3A).

Moreover, HMGB1–RAGE pathway stimulates Yap1 by direct association with K-Ras and results in CRC progression. Many pathways are activated through HMGB1–RAGE interaction including MAPK, Ras, Hippo, and Wnt/β-catenin signaling pathways as classic oncogenic pathways in CRC cells. Yap1 and β-catenin are physically linked to each other to enhance the Wnt target transcription in CRC cells, proposing that Wnt/β-catenin pathway possibly will contribute to CRC progression by RAGE activation trigger, which should be more elucidated in future studies (165) (Figure 3A).

Furthermore, HMGB1 and RAGE interaction activates MAPK signaling pathway through K-Ras, Rac1/INK/SAPK, and ERK1/2/Drp1 phosphorylation and prompts CRC progression, chemoresistance and regrowth of cancer cells, and colonic myofibroblast proliferation, migration, and invasion (57, 158, 165, 166). Mitochondrial dysfunction has been shown to progress cancer cell proliferation, decrease apoptosis, and increase chemoresistance (170). HMGB1 is released from dying cells by chemotherapeutic drugs in conditioned medium and interacted with RAGE, signals ERK1/2 activation to phosphorylate Drp1 at residue S616, triggering mitochondria fission and autophagy, and promotes chemoresistance and regrowth in the surviving cancer cells, leading to poor survival outcome in locally advanced rectal cancer. HMGB1 inhibitor and RAGE blocker ablished Drp1 phosphorylation and considerably increased chemotherapeutic cure sensitivity by suppressing autophagy. Moreover, it has been shown that high phospho-Drp1Ser616 in CRC patients is related to a high possibility of developing tumor relapse. Moreover, RAGE-G82S polymorphism (rs2070600) has high ligand affinity and is related to high phospho-Drp1Ser616 in tumor microenvironment (57) (Figure 4).

Lue et al. indicated that after HMGB1 elevation in serum and colon of mice model of colon cancer, autophagy increased, which led to elevation of free amino acids in plasma, increased glutamine, and low PKM1 levels through activation of RAGE by HMGB1. HMGB1 enhanced autophagy in the muscle by decreasing active mTOR and augmentation of autophagy-related proteins and plasma glutamate. These aberrant effects were abolished by administration of an HMGB1-neutralizing antibody. So, this glutamine released from necrotic cells is used by the remnant cancer cell as an energy source and support their continuous growth (9). Moreover, Luo et al. in another study showed that necrosis inducer promotes cancer cell necrosis and releases HMGB1, which enhances regrowth and metastasis of remnant cancer cells by RAGE activation, but apoptosis inducers lack this effect. Thus, the outcomes proposed using apoptosis inducers more than necrotic inducers to prevent cancer relapse (171) (Figure 4).

Trophinin, a unique adhesion molecule, is expressed in human trophoblastic cells, with a pivotal role in trophoblast growth and invasion into the uterine wall to form the placenta (172). This process resembles tumor invasion into adjacent tissues. Trophinin is expressed in testicular germ cell tumors, leading to invasion and metastasis of tumor cells (173). Harada et al. indicated that SW480 cells that highly expressed trophinin and HMGB1 were more invasive than control. Small interfering RNA (siRNA) knockdown of trophinin reverses its effect in Colo320 cells. Positive correlation was found between HMGB1 protein expression in the nucleus and trophinin expression in tumor tissues, and its high expression in tumors of colon cancer patients is strongly linked to poor prognosis. Moreover, they investigated tumor tissues of 50 CRC patients and found HMGB1 and RAGE protein coexpression in 65.6% of trophinin-positive patients. Thus, it could be concluded that trophinin stimulates invasion via a mechanism involving HMGB1/RAGE (86).

Thus, as shown in Figures 3, 4, HMGB1–RAGE interactions on surface of tumor cells, inflammatory cells, and also muscle cells provide an inflammatory microenvironment that promotes chemoresistance and cancer cell regrowth via activating MAPK, PI3K, Wnt/β-catenin, and NF-κB signaling pathway. Also, blocking HMGB1–RAGE interaction could enhance chemotherapy sensitivity.

S100A8/9
S100A8/A9 interaction with RAGE activates MAPK, Smad4, and NF-κB signaling pathways and develops intestinal adenoma, migration, invasion, and metastasis (11, 45, 108, 109, 121). Studies have shown that S100A8/A9 expression on myeloid cells is necessary for colon tumor growth (109). As recruited monocytes mature, they lose S100A8 and keep S100A9 expression and recruit more inflammatory cells, resulting in tumor cell proliferation and invasion. S100A8/9 boosted migration and proliferation in cells with or without Smad4 tumor cells. But, tumor cells with transient decrease of Smad4 do not react to S100A8, but not S100A9. Interaction of tumor cells with stromal myeloid cells and reaction to stromal chemokine are altered with loss of Smad4. S100A/S100A9 makes Smad4 signaling active as shown by phosphorylation of Smad2/3; RAGE blockade repressed this reaction (108) (Figure 5).

MDSCs suppress the antitumor immune response and enhance tumor growth and metastasis. It has been found that increased levels of S100A9 and MDSCs in
FIGURE 3 | HMGB1 makes a metastatic microenvironment. (A) Glucose imbalance is an HMGB1 elevation trigger in tumor microenvironment by activating MAPK/ERK, Wnt/β-catenin, and PI3K pathways. (B) HMGB1–RAGE interaction results in both apoptosis and antiapoptosis via activation of, respectively, Rac1/Cdc42/JNK and NF-κB pathways.
FIGURE 4 | HMGB1 makes tumor cells resistant to chemotherapy. HMGB1 released from chemotherapy dying cancer cells in the tumor microenvironment and HMGB1–RAGE interaction on cancer cells lead to mitochondria fission, and autophagy via ERK1/2-dependent Drp1 phosphorylation enhances chemoresistance status. Besides, RAGE activation on muscle cells initiates muscle degradation, and releasing amino acids such as glutamine in the circulation and tumor environments provides energy source for sustaining growth of tumor cells.
FIGURE 5 | S100A8/A9 provides a premetastatic environment. S100A8/A9 expresses on tumor cells and also inflammatory cells. S100A8/A9–RAGE interaction results in activation of Smad, NF-κB, ERK1/ERK2, and SAPK/JNK pathways and increasing the leukocyte recruitment angiogenesis, tumor migration, and wound healing and consequently providing premetastatic niches. MDSCs will promote immunosuppressive microenvironment by activation of NF-κB pathway and also cause chemotaxis by P38 activation.
tumor tissue and peripheral blood of CRC patients were related to neoplastic progression. Moreover, S100A9 regulates MDSC chemotaxis and activation, which induces immunosuppressive microenvironment. Elevated S100A9 in tumor microenvironment released from cancer cells, inflammatory cells, or MDSCs fuels RAGE-dependent p38 MAPK signaling cascade and also the TLR4-dependent NF-κB signaling cascade. Activation of p38 MAPK pathway led to MDSC chemotaxis, and NF-κB activation led to upregulation of immunosuppressive molecules inducible NO synthase (iNOS), Arg-1 and IL10 expression, and ROS production. Thus, assessing S100A9 and MDSCs in tumor tissue and also peripheral blood could help as a diagnostic marker of CRC progression (121). However, Ichikawa et al. indicated that S100A8/A9–RAGE and carboxylated glycan interaction activates phosphorylation of ERK1/ERK2 and SAPK/JNK MAPK in colon tumor cells, but not significant p38 phosphorylation, which led to elevation of Slec39a10, Cxcl1, Cc5, Enpp2, Ccl7, Lcn2, Zc3h12a, and other genes, and stimulates recruitment of leukocytes, angiogenesis, migration of tumor cells, wound soothing, and creation of premetastatic microenvironment (109). Carboxylated glycans are expressed on a RAGE subpopulation on colon tumor cells and facilitate S100A8/A9 binding to RAGE results in NF-κB activation and cancer cell proliferation. S100A8/A9 could also activate TLR4 and increased tumorigenicity. Anticarboxylate glycan antibody blocks RAGE–ligand binding, downstream signaling, and tumor cell proliferation (11) (Figure 5).

In summary, tumor cells respond to S100A9 better than S100A8, and its interaction with RAGE triggers different signaling pathways in favor of inflammatory tumor microenvironment, including Smad, NF-κB, MAPK/ERK, and SAPK/JNK and P38, leading to leukocyte recruitment, angiogenesis, tumor migration, wound healing, and premetastatic niches. Also MDSCs act as immune suppressor cells in tumor microenvironment and could be good tumor progression marker.

**S100A4**

Interaction of S100A4–RAGE mediates MAPK/ERK and hypoxia signaling hyperactivation, leading to elevated CRC cell motility, which is significantly enhanced by adding sR100A4 (40). Sack et al. showed calcimycin inhibits promoter of S100A4 and decreases S100A4 expression and therefore impairs inducing of cell motility and metastasis, via suppression of Wnt/β-catenin pathway activity and expression of important β-catenin target genes such as S100A4, cyclin D1, c-myc, and dickkopf-1 (127) (Figure 6).

**S100P**

While RAGE expresses in both normal and malignant colon specimens, S100P is expressed only in the malignant specimens and promoted cell growth; migration through RAGE activation, which leads to ERK1/2 phosphorylation; and NF-κB activation. In line with this, it has been shown that treatment of colorectal cancer cell lines with S100P increased proliferation and cell migration. Antagonism of RAGE blocked this interaction and irregular results (8). Moreover, Shen et al. showed that S100P and RAGE interaction leads to ERKs phosphorylation and promotes EMT (154). S100P expression is regulated by transcription factors and microRNA. Both SOX9 and S100P are overexpressed in colon cancer. SOX9, S100P transcription factor, increased S100P expression promote metastasis and invasion and result in low survival in colon cancer patients (153). Furthermore, studies show that microRNA dysregulation mediates cancer development and progression through activation of inflammatory cascades. MiR-21 is overexpressed in many types of human cancers, as well as colon cancer. S100P/RAGE interaction activates ERK1/2 phosphorylation, leading to the upregulation of oncopgenic miR-21 via AP-1 signaling pathway, which leads to RECK suppression, and facilitates the onset of invasion and metastasis (163). Moreover, RAGE–S100P interaction activates MAPK pathway, and AP-1 leads to expression of oncopgenic miR-155 expression, implicated in several malignancies such as colon cancer by linking inflammation and cancer. Prominent levels of miR-155 have been detected in primary colon cancers and metastatic lesions. It has been shown that exogenous S100P cannot activate MAPK-dependent miR-155 after suppressing activation of AP-1 by inhibiting MEK activation or genetically inhibiting c-Jun activation. Thus, miR-155 was regulated by MAPK kinase and also, to a lesser extent, NF-κB (164, 174–177) (Figure 7).

In conclusion, S100P is only expressed in malignant tissues that result in EMT by activating MAPK/ERK1/2 and S100P accumulation that initiates NF-κB activation and AP-1-dependent oncogenic miRNA activation, which altogether enhanced tumor migration and invasion.

**THERAPEUTIC STRATEGIES AGAINST RAGE IN CRC**

As shown in many studies mentioned in this review investigating the role of RAGE by its blockage through siRNA and antibodies and antagonists treatment, RAGE activation stopped, as well as underlying mechanisms leading to tumorigenicity. Also, it has been indicated that antibodies against RAGE ligands can decrease the risk of CRC (178–182). This, as mentioned before, the effect of prolonged RAGE blockade in human subjects is important because RAGE plays vital roles in normal physiology. Moreover, 30 percent of IBD patients did not respond to anti-TNF-α and other therapeutic options such as antibodies against cytokines that promote infection in patients (183, 184). In this regard, few studies investigated the effect of less toxic therapeutic agents such as ligand-scavenging components such as phytochemicals. Flavonoids, stilbenes, catechins, phenolic acid, anthocyanin, genistein, and curcumin are mentioned as AGE formation inhibitors and lead to decreased risk of diabetes and CRC (185–188). Fluoroquinolones are promising therapeutic agents for increasing the related α-dicarbonyl (AGE precursors) scavengers as to protect cells against carbonyl stress (189). Heat-stabilized rice bran consumption in colorectal patients has been indicated in the modulation of stool metabolites such as AGEs (190). Also, medicinal plants such as *Carpobrotus edulis* (African) as well as *Castanea mollissima* Blume (Chinese) work...
FIGURE 6 | S100A4 increased motility of tumor cells. S100A4–RAGE interaction in tumor cells initiates activation of hypoxia, and MAPK/ERK signaling results in Wnt-β pathway activation and expression of β-catenin target genes, which promote elevated CRC cell motility. Calcimycin by suppressing the S100A4 promoter decreases S100A4 expression and other genes and inhibits Wnt-β pathway reverse S100A4 effect.

against protein glycation and colon cancer by inhibition of AGE production (191, 192). Therefore, novel phytochemical components by inhibiting RAGE activation could be less toxic and safer to approach against cancer.

AGES-RAGE INTERACTION REGARD TO T2D AND CRC ASSOCIATION

Lifestyle in industrialized countries, such as physical inactivity and diet, leads to increased mortality and threat to public health in the world. Many studies have revealed that obesity, chronic inflammation, aging, and insulin resistance are associated risk factors inducing CRC development (193–195). Moreover, T2D could decrease the survival of CRC patients. The evidence has shown that elevated insulin concentration is able to develop CRC cell growth, but the mechanism and molecular link between CRC and T2D are controversial (196–198). However, metabolic syndrome, especially insulin resistance and hyperglycemia, could explain the relationship between these diseases (199, 200). Nevertheless, there was a missing link in related signaling pathways. Yamagishi et al. hypothesized that RAGE and enhanced serum AGEs were the bridge between associated diseases and increase the risk of colorectal cancer in patients with diabetes (201). Upregulated RAGE and its ligands have been indicated in different inflammatory conditions, including IBD, diabetes, and cancer (54). Based on these studies, RAGE has essential roles in tumorigenesis, and metastasis–ligand–RAGE axis plays a vital role in sophisticated paracrine and autocrine manners within the tumor microenvironment to promote cell migration, invasion, and survival (27, 202, 203). Particularly, Liu et al. in 2014 enrolled 21 CRC patients with metabolic syndrome, and they found that IL-6, IGF-1, and VEGF-1 circulation was unchanged. However, IGF-1R and RAGE expressions were increased in tumor tissues; also, fasting insulin levels in CRC patients with metabolic syndrome were significantly enhanced (151). Moreover, Deng and colleagues have shown the risk of CRC in diabetic patients significantly increased, and glucose-derived AGEs were increased in CRC patients serum and activate RAGE/ERK/SP1/matrix metallopeptidase-2 (MMP2) cascade in cancerous tissues promote the invasion and metastasis of CRC. This is reversed by RAGE blocking Ab and SP1-specific siRNA.
RAGE-associated genes were upregulated including MMP9, VEGF, iNOS, and BCL2 in the carcinomas. The phosphorylation of ERK1/2, Rac1, and AKT and the production of MMP9 are increased more by HMGB1 than by AGE, whereas the production of iNOS and NF-κB is increased more by AGE than by HMGB1. AGE–RAGE induced by high-LA and high-glucose diets substantially enhances colon cancer development (41, 150, 162). Moreover, some transcription factors, such as SP1, p53, NF-κB, and KLF7, could regulate oncogenic gene. MDM2 and MDM2 overexpression is a candidate biological link between T2D and colon cancer development. Wang et al. in 2018 indicated that diabetes increases the level of AGE, which enhances the expression of MDM2 via transcription factor KLF5.

Deng et al. demonstrated the expression of specificity protein 1 (Sp1), MMP2, and RAGE predominately increased in cancerous tissues (72). AGE and RAGE were unregulated in the colonic mucosa of azoxymethane (AOM)-injected F344 rats, especially in rats fed with high-LA and high-glucose diets, and this upregulation induced continuous ROS production and was associated with increased ACFs and carcinomas in the rat colon. Moreover, treatment with metformin and losartan inhibited AGE and reduced cancer multiplicity in the rats that received LA or normal diet and glucose drink in comparison to the control rats. Losartan showed mild inhibition of AGE formation in a non-cellular system, suggesting that losartan possesses a weak antioxidative effect independent of its antiangiotensin activity.
in colon cells. MDM2 binds directly to cancer suppressors; p53 and Rb promote their inactivation and degradation (73). Additionally, Kuniyasu et al. claimed that invasion and metastasis are associated with raised expression of RAGE and amphoterin in 119 non-diabetic patients with CRC (150). Besides, several studies have suggested inflammation has a prominent role in IBD that is associated to amplified risk of CRC (204–206). Nevertheless, Kong et al. showed that in a total of 1,055 CRC cases glycer-AGEs levels were raised; however, this was not related to colon risk. As a result, AGES were not associated with amplified risk of colorectal cancer (69). AGES are able to affect the antioxidant defenses and augmented ROS and apoptosis (207, 208). However, Kucukhuseyin et al. detected increased level of advanced oxidation protein products and protein carbonyl in CRC patients, and the levels of antioxidants such as Cu-Zn SOD and total thiol were lessened (149). In another study, Sakellaridou et al. in 2016 claimed that there was a relationship between RAGE and detoxification enzyme GLO-I and adiponectin receptors (AdipoR1, AdipoR2) in CRC. They investigated 133 primary CRC cases and found that RAGE and AdipoR1 might be involved in CRC; also, the upregulation of AdipoR2 and GLO-I reduced survival in the whole cohort and early-stage cases. Notably, redox levels as biomarkers in CRC predominate were changed. These data were in agreement with those of Thornalley et al. (76, 209). In general, the accumulation AGES and binding to RAGE lead to activation and oligomerization of various inflammatory and oxidative stress.

The mechanism of abnormal epithelial proliferation under the diabetic state is unclear. Several literatures have shown that gut microbiota has a pivotal role in intestinal disease (210, 211). Moreover, the level of HMGB1 is elevated in the serum of these related diseases. Interestingly, Wang et al. in 2019 have attempted to observe the association of hyperproliferation of colonic epithelium under a diabetic state with RAGE and HMGB1; besides, they investigated the influence of butyrate on the proliferation of NCM460 cells. Notably, Wang and colleagues indicated that high glucose state increased proliferation by overexpression of HMGB1 and RAGE. On the other hand, butyrate could be suppressed, enhancing proliferation by targeting HMGB1. These data have shown that butyrate inhibited the expression of RAGE and prevented AGES accumulation (169). Arabiyat et al. synthesized antioxidative and anti-inflammatory molecules, including fluoroquinolones and triazolofluoroquinolones, which could be suppressed in the AGES binding to RAGE, and accumulation of AGES was inhibited as a consequence. Moreover, this study evaluated the potential antiproliferative efficacy against colorectal cancer cell lines, as well as obesity and diabetes (189). Furthermore, Zhang et al. have explored C. mollissima Blume (Chinese chestnut) enriched by flavonoids, and polyphenolic acids might have anti-diabetic complications and anticancer activities (192). A recent study has shown that some miRNA levels are involved in CRC and T2D, and lifestyle could influence these diseases. A study by Zhu et al. in 2019 revealed the relationship between miR-99a and mTOR in 20 patients with CRC and T2D. They found AGES could impair the miR-99a, leading to overactivated mTOR signaling. In addition, microarray analysis indicated this miRNA might be a biomarker and therapeutic target (177).

Recently, elevated levels of MG were found in mammals consuming a Western-style diet. MG is derived from glycolysis, lipid peroxidation, and protein degradation. Many studies demonstrated that MG-induced carbonyl stress can lead to oxidative stress and inflammation, and it was highlighted in the pathogenesis of obesity, diabetes, and metabolic syndrome (75). Exposure to MG led to increases in the serum low-density lipoprotein/high-density lipoprotein ratio, fecal bile acid, and feci of aberrant crypts in the colon (ACFs) and aberrant crypts (ACs) in the colon of AOM-treated mice, and oxidative and carbonyl stress (MG, AGES, and malondialdehyde levels) inflammatory mediators (IL-6 and RAGE) in tumors of CT26 isografts in mice. Also, increased activation of signaling pathways that modulate cell survival and proliferation (i.e., the ERK/p38 MAPK, and PI3K/GSK3β/mTOR pathways) and increased level of GLO and Sirt1 were observed in MG-induced cells with increased proliferative and migratory activities as well as stem-like properties (increased CD29). Excitingly, boosted expression or activation of proteins that modulate cell survival, proliferation, or migration/invasion (such as vimentin) was also observed. MG-induced carbonyl stress may be the pivotal agent involved in colon cancer progression. Furthermore, high level of MG adducts and low GLO-I activity in high stage tumors promote CRC development and tumor growth, which is reversed by carnosine, a potent MG scavenger (74, 75).

Thus, it could be concluded that different AGE subtypes and derivatives are accumulated in T2D and by interaction with RAGE trigger detrimental procedures, leading to increased inflammation and ROS production end in microenvironments, which increases the risk of CRC.

**CONCLUDING REMARKS**

At present, convincing evidence indicates RAGE activation makes a tumor-promoting milieu, which in turn favors proliferation and survival of colorectal cancer cells. In this circumstance, developing investigational data propose that the multiligand–RAGE axis may be a significant contributor to inflammation-related tumorigenesis through different signaling mechanisms including activation of AP-1, NF-κB, STAT3, SMAD family members, MAPKs, mTOR, PI3K, Ras, Wnt/β-catenin, and GSK3β and even microRNAs, which epigenetically regulates the expression of RAGE ligands. These contain the activation of crucial processes that might help in the resistance to apoptosis and hypoxia, getting involved in antitumor immunity, provoking immunosuppressive microenvironment, increasing angiogenesis, and helping invasiveness. So, multiligand–RAGE axis has developed a very interesting target for pharmacological interventions directed to block RAGE–ligand interactions at the receptor level and also inhibited by scavenging its ligands. But as the function of RAGE and its ligands is tissue specific and has a role in normal physiology, as well as different pathologies, approaching appropriate therapeutic strategies are important. However, various questions remain unanswered to completely comprehend the role of this receptor in tumor–host cells interactions, particularly the other ligands that activate RAGE, the recruitment and activation of MDSCs, and the cross-talk between RAGE and TLRs.
AUTHOR CONTRIBUTIONS

FA-F: conception, providing the data and design, and manuscript writing. KG, MN-E, AG, and MH: conception and final approval of manuscript. NA: conception, providing the data and design, and manuscript writing. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. (2014) 64:104–17. doi: 10.3322/caac.21220
2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. (2017) 66:683–91. doi: 10.1136/gutjnl-2015-310912
3. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. (2014) 12:661–72. doi: 10.1038/nrmicro3344
4. Zoratto F, Rossi L, Verrico M, Papa A, Basso E, Zullo A, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. Tumor Biol. (2014) 35:6195–206. doi: 10.1007/s13277-014-1845-9
5. Siegel RL, Miller KD, GOLDING A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. (2020) 70:145–64. doi: 10.3322/caac.21601
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. (2000) 100:57–70. doi: 10.1016/S0092-8674(00)81683-9
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
8. Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC, et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum. (2007) 50:1230–40. doi: 10.1097/DCR.0b013e318060850-5
9. Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, et al. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer. (2013) 49:741–51. doi: 10.1016/j.ejca.2012.09.016
10. Neep ER, Schmidt A, Brett J, Yan S, Wang F, Pan Y, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. (1992) 267:14998–5004.
11. Turovskaya O, Foell D, Sinha P, Vogt T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. (2008) 29:2035–43. doi: 10.1093/carcin/bgn188
12. Prasad C, Imran V, Marotta F, Juma S, Vijayagopal P. Lifestyle and advanced glycation end products (AGEs) burden: its relevance to healthy aging. Aging Dis. (2014) 5:212. doi: 10.14336/AD.2014.050212
13. Walter KR, Ford ME, Gregoski MJ, Kramer KD, Knight KD, Spruill L, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. (2008) 22:1572–80. doi: 10.1096/fj.07-9900com
14. Basta G. Receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. (2006) 13:1971–8. doi: 10.2174/156722606777585013
15. Rojas A, Mercadal E, Figueroso H, Morales MA. Advanced Glycation and ROS: a link between diabetes and heart failure. Curr Vasc Pharmacol. (2008) 6:44–51. doi: 10.2174/157016108783331312
16. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. (2008) 22:1572–80. doi: 10.1096/fj.07-9900coma
17. Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and disease. Front Biosci. (2011) 17:2756–70. doi: 10.2741/3884
18. Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci. (2009) 116:621–37. doi: 10.1042/CS20080494
19. Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. BioMed Res Int. (2010) 2010:917108. doi: 10.1155/2010/917108
20. Malik P, Chaudhry N, Mittal R, Mukherjee TK. Role of receptor for advanced glycation end products in the complication and progression of various types of cancers. Biochim Biophys Acta Gen Subj. (2015) 1850:1899–904. doi: 10.1016/j.bjbag.2015.05.020
21. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response—the evidence mounts. J Leukocyte Biol. (2009) 86:505–12. doi: 10.1189/jlb.0409230
22. Singh VP, Bali A, Singh N, Jaggil AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. (2014) 18:1–14. doi: 10.4196/kjpp.2014.18.1.1
23. Kim J, Wan CKJ, O’carroll S, Shaikh SB, Nicholson LF. The role of receptor for advanced glycation end products (RAGE) in neuronal differentiation. J Neurosci Res. (2012) 90:1136–47. doi: 10.1002/jnr.23014
24. Puu S, Rosi M, Gagnon P, Hossain T, Bouchard M, Gagnon M, et al. Metabolome and gut microbiota composition in patients with colorectal cancer. Gut Microbes. (2015) 6:261–73. doi: 10.1080/19490976.2014.941717
25. Konopka CJ, Wozniak M, Hedhli J, Siekierzycka A, Nix M, et al. Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer. Eur J Nucl Med Mol Imag. (2020). doi: 10.1007/s00259-020-04721-1. [Epub ahead of print].
26. Sharma AK, Sharma VR, Gupta GK, Ashraf GM, Kamal MA. Advanced glycation end products (AGEs), glutathione and breast cancer: factors, mechanism and therapeutic interventions. Curr Drug Metab. (2019) 20:65–71. doi: 10.2174/1879201219668180912104342
27. Turner D, Krisanits B, Frye C, Nogueira L, Schuster R, Ford M, et al. Consumption of dietary advanced glycation end products promotes prostate tumor growth by creating a tumor enhancing stromal microenvironment. Curr Dev Nutr. (2020) 4:339. doi: 10.1093/cdn/nzaa044_058
36. Guo Y, Zhang H-C, Xue S, Zheng J-H. Receptors for advanced glycation end products is associated with autophagy in the clear cell renal cell carcinoma. J Cancer Res Ther. (2019) 15:317–23. doi: 10.4103/jcrt.JCRT_180_18
37. Jing R, Cui M, Wang J, Wang H. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma. (2010) 57:55. doi: 10.4149/neop_2010_01_055
38. Omofuma OO, Turner DP, Peterson LL, Merchant AT, Zhang J, Steck SE. Dietary advanced glycation end-products (AGEs) and risk of breast cancer in the prostate, lung, colorectal and ovarian cancer screening trial (PLCO). Cancer Prev Res. (2020) 13:601–10. doi: 10.1158/1940-6207.CAPR-19-0457
39. Tsujimoto H, Horiguchi H, Takahata R, Ono S, Yaguchi Y, Nomura S, et al. Impact of perioperative high mobility group box chromosomal protein 1 expression on long-term outcomes in patients with esophageal squamous cell carcinoma. J Gastroenterol Hepatol. (2020) 35:788–94. doi: 10.1111/jgh.14854
40. Dahlmann M, Okhrimenko A, Marcinkowski P, Osterland M, Herrmann P, Smith I, et al. RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget. (2014) 5:3220–33. doi: 10.18632/oncotarget.1908
41. Shimomoto T, Luo Y, Ohmori H, Chihara Y, Fujii K, Sasahira T, et al. Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of aoxymethone-injected Fischer 344 rats fed with a high-inoic acid and high-glucose diet. J Gastroenterol. (2012) 47:1073–80. doi: 10.1530/JG-11-0296
42. Kostova N, Zlateva S, Ugrinova I, Pashева E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. (2010) 337:251–8. doi: 10.1007/s11010-009-0305-0
43. Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases. Nature. (2000) 405:354–60. doi: 10.1038/35012626
44. Chen P, Zhao J, Gregersen H. Up-regulated expression of advanced glycation end-products and their receptor in the small intestine and colon of diabetic rats. Digest. Dis. Sci. (2012) 57:48–57. doi: 10.1007/s10620-011-1951-0
45. Heijmans J, Builer NVJA, Hoff E, Dibal AA, van Der Poll T, van Zoelen MAD, et al. RAGE signalling promotes intestinal tumourigenesis. Oncogene. (2013) 32:1202–6. doi: 10.1038/onc.2012.119
46. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands—cast into leading roles in diabetes and the inflammatory response. J Mol. Med. (2009) 87:235–47. doi: 10.1007/s00428-008-0439-2
47. Stern D, Du Yan S, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress and inducers of cell death. Drug Deliv. (2005) 2:1615–25. doi: 10.1007/s10299-005-0160-6
48. Liang H, Zhong Y, Zhou S, Peng L. Knockdown of RAGE expression inhibits expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int J Oncol. (2012) 39:957–63. doi: 10.3892/ijo.2011.1610
49. Tateno T, Ueno S, Hiwatashi K, Matsumoto M, Okumura H, Setoyama T, et al. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. (2009) 16:440–6. doi: 10.1245/s10434-008-0237-z
50. Ruizzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol. (2007) 171:947–61. doi: 10.2353/ajpath.2007.070049
51. Ruizzi F, Sorci G, Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem. (2006) 281:8242–53. doi: 10.1074/jbc.M50943 36200
52. Bartling B, Hofmann H-S, Weigel B, Silber R-E, Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis. (2005) 26:293–301. doi: 10.1093/carcin/bgh333
53. Schraml P, Shipman R, Colombi M, Ludwig CU. Identification of genes differentially expressed in normal lung and non-small cell lung carcinoma tissue. Cancer Res. (1994) 54:5236–40.
Azizian-Farsani et al. RAGE and Colorectal Cancer

72. Deng R, Wu H, Han R, Kong X, Hu L, Wang X, et al. Glucose-derived AGEs promote migration and invasion of colorectal cancer by up-regulating Sp1 expression. Biochem Biophys Acta Gen Subj. (2017) 1861:1065–74. doi: 10.1016/j.bbagen.2017.02.024

73. Wang P, Lu YC, Li YF, Wang L, Lee SC. Advanced glycation end products increase MDMB2 expression via transcription factor KLF5. J Diabetes Res. (2018) 2018:3274084. doi: 10.1155/2018/3274084

74. Chiavarini B, Nokin M-J, Bletier N, Sharer F, et al. Methyglyoxal-mediated stress correlates with high metabolic activity and promotes tumor growth in colorectal cancer. Int J Mol Sci. (2017) 18:2123. doi: 10.3390/ijms18012123

75. Lin J-A, Wu C-H, Yen G-C. Methylglyoxal displays colorectal cancer-promoting properties in the murine models of axoneme and CT26 isografts. Free Radical Biol Med. (2018) 115:436–46. doi: 10.1016/j.freeradbiomed.2017.12.020

76. Sakellarious P, Fragkou P, Levidou G, Gargalionis AN, Piperi C, Dalagiorgou G, et al. Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-1, adiponectin receptor expression and prognosis. BMC Cancer. (2016) 16:174. doi: 10.1186/s12885-016-2213-5

77. Parkkala J, Raulo E, Merenemies J, Nolo R, Kajander EO, Baumann M, et al. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem. (1993) 268:19726–38.

78. He S-J, Cheng J, Feng X, Yu Y, Tian L, Huang Q. The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget. (2017) 8:64534–50. doi: 10.18632/oncotarget.17885

79. Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Regulation of cell localization of HMGB1, a chromatin protein with a cytokine function. J Cell Sci. (2000) 113:611–20.

80. Ohmori H, Luo Y, Kuniyasu H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets. (2011) 15:183–93. doi: 10.1517/14728222.2011.546785

81. Volp K, Brezniceanu M-L, Bösser S, Bräbtz T, Kirchner T, Göttel D, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. (2006) 55:234–42. doi: 10.1136/gut.2004.062729

82. Tang D, Kang R, Livesey KM, Cheh C-W, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. (2010) 190:881–92. doi: 10.1083/jcb.200911078

83. Müller S, Ronfani L, Bianchi M. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Int Med. (2004) 255:332–43. doi: 10.1111/j.1365-2796.2003.01296.x

84. Wang P, Lu YC, Li YF, Wang L, Lee SC. Advanced glycation end products increase MDM2 expression via transcription factor KLF5. J Diabetes Res. (2018) 2018:3274084. doi: 10.1155/2018/3274084

85. Lin J-A, Wu C-H, Yen G-C. Methylglyoxal displays colorectal cancer-promoting properties in the murine models of axoneme and CT26 isografts. Free Radical Biol Med. (2018) 115:436–46. doi: 10.1016/j.freeradbiomed.2017.12.020

86. Völp K, Brezniceanu M-L, Bösser S, Bräbtz T, Kirchner T, Göttel D, et al. Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-1, adiponectin receptor expression and prognosis. BMC Cancer. (2016) 16:174. doi: 10.1186/s12885-016-2213-5

87. Parkkala J, Raulo E, Merenemies J, Nolo R, Kajander EO, Baumann M, et al. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem. (1993) 268:19726–38.

88. He S-J, Cheng J, Feng X, Yu Y, Tian L, Huang Q. The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget. (2017) 8:64534–50. doi: 10.18632/oncotarget.17885

89. Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Regulation of cell localization of HMGB1, a chromatin protein with a cytokine function. J Cell Sci. (2000) 113:611–20.
111. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol. (2003) 170:3233–42. doi: 10.4049/jimmunol.170.6.3233

112. Foell D, Wittkowski H, Vogt T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. (2007) 81:28–37. doi: 10.1189/jlb.0306167

113. Zwandl G, Brüggen J, Gerhards G, Schlegel R, Sorg C. Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol. (1988) 72:510–5.

114. Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microbes Infect. (2003) 60:569–80. doi: 10.1016/j.micinf.2002.08.028

115. Roth J, Vogl T, Sorg C, Sunderkötter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol. (2003) 24:155–8. doi: 10.1016/S1471-4903(03)00062-0

116. Roth J, Goebeler M, Sorg C. S100A8 and S100A9 in inflammatory diseases. Lancet. (2003) 362:947–52. doi: 10.1016/S0140-6736(03)13627-2

117. Huang L-Y, Xu Y, Cai G-X, Guan Z-Q, Sheng W-Q, Lu H-F, et al. Functional significance of metastasis-inducing S100A4 (Mst1) in tumor-stroma interplay. J Biol Chem. (2004) 279:24498–504. doi: 10.1074/jbc.M400441200

118. Van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem. (2009) 284:13804–11. doi: 10.1074/jbc.M901351200

119. Schmidt-Hansen B, Kleinigkötter F, Grum-Schwensen B, Christensen A, Andresen S, Kruse C, et al. Functional significance of metastasis-inducing S100A4 (Mst1) in tumor-stroma interplay. J Biol Chem. (2004) 279:24498–504. doi: 10.1074/jbc.M400441200

120. Somora A, Morejon MJ, Onichichenko A, Abulrob A, Ball M, Eklil E, et al. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem. (2005) 280:20383–41. doi: 10.1074/jbc.M4063290

121. Becker T, Gerke V, Kube E, Weber K, S100p, a novel Ca2+-binding protein from human placenta: cDNA cloning, recombinant protein expression and Ca2+-binding properties. Eur J Biochem. (1992) 207:541–7. doi: 10.1111/j.1432-1033.1992.tb07080.x

122. Ding Q, Chang C-J, Xie X, Xia W, Yang J-Y, Wang S-C, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. (2011) 121:4526–36. doi: 10.1172/JCI45008

123. Liang J, Lai Y-K, Zhang J, Wang H, Lin M-C, He M-L, et al. Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol Med. (2011) 17:709–16. doi: 10.2119/molmed.2011.00008

124. Chandramouli A, Mercado-Pimentel ME, Hutchinson A, Gibadullinova A, Olson ER, Dickinson S, et al. The induction of S100p expression by the Prostaglandin E2 (PGE2)/EP4 receptor signaling pathway in colon cancer cells. Cancer Biol Ther. (2010) 10:1056–66. doi: 10.1161/jcb.109.226243

125. Wang Q, Zhang Y-N, Lin G-L, Qiu H-Z, Wu B, Wu H-Y, et al. S100P, a potential novel prognostic marker in colorectal cancer. Oncol Rep. (2012) 28:303–10. doi: 10.3892/or.2012.1794

126. Caruso MG, Notarnicola M, Altmare DF, Misciagna G. Gene expression of fructosamine 3 kinase in patients with colorectal cancer. Oncology. (2007) 73:72–7. doi: 10.1159/000120631

127. Chen L, Duan Z, Tinker L, Sangi-Haghpeykar H, Strickler H, Ho GY, et al. A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women. Cancer Epidemiol Prev Biomarkers. (2016) 25:1148–54. doi: 10.1158/1055-9965.EPI-15-0593

128. Choi S, Yang SY, Choi GJ, Kim BG, Kang H. Comparison of pressure-volume and volume-controlled ventilation during laparoscopic colectomy in patients with colorectal cancer. Sci Rep. (2019) 9:10.3892/sor.2019.1724

129. Comstock SS, Xu D, Horts K, Kovan B, Mccaskey S, Pathak DR, et al. Association of insulin-related serum factors with colorectal polyp number and type in adult males. Cancer Epidemiol Prev Biomarkers. (2014) 23:1843–51. doi: 10.1158/1055-9965.EPI-14-0249-T

130. Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, et al. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI for colorectal cancer patients beyond RECIST. Cancer Sci. (2019) 110:3565–72. doi: 10.1111/cas.14198
148. Jiao L, Chen L, Alsaaraj A, Ramsey D, Duan Z, El-Serag HB. Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma. *Int J Mol Epidemiol Genet*. (2012) 3:294–304.

149. Kucukhuseyin O, Turan S, Yanar K, Arikian S, Duzkoylu Y, Aydin S, et al. Individual and combined effects of CTLA4–CD28 variants and oxidant–antioxidant status on the development of colorectal cancer. *Anticancer Res*. (2015) 35:5391–400.

150. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. *Onco Res*. (2003) 10:445–8. doi: 10.3892/or.10.2.445

151. Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, et al. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process? *J Geriatr Oncol*. (2014) 5:40–8. doi: 10.1016/j.jgo.2013.11.004

152. Roys E, Chen L, Berger DH, Ittmann MM, El-Serag HB, Balentine CJ, et al. Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. *Int J Mol Epidemiol Genet*. (2017) 8:8–18.

153. Shen Z, Deng H, Fang Y, Zhu X, Ye G-T, Yan L, et al. Identification of the interplay between SOX9 and S100P in the metastasis and invasion of colon carcinoma. *Onco Target*. (2015) 6:20672–84. doi: 10.18632/oncotarget.3967

154. Shen ZY, Fang Y, Zhen L, Zhu XJ, Chen H, Liu H, et al. Analysis of the predictive efficiency of S100P on adverse prognosis and the pathogenesis of S100P-mediated invasion and metastasis of colon adenocarcinoma. *Cancer Genet*. (2016) 209:143–53. doi: 10.1016/j.cancergen.2016.02.002

155. Töth ÉK, Kroics J, Madaras B, Bíró Á, Pocsai Z, Fust G, et al. The 8.1 ancestral MHc haplotype is strongly associated with colorectal cancer risk. *Int J Cancer*. (2007) 121:1744–8. doi: 10.1002/ijc.22922

156. Zítczuk J, Maciejczyk M, Zaraéh K, Romaniuk W, Markowski A, Kadra B, et al. Antioxidant barrier, redox status, and oxidative damage to biomolecules in patients with colorectal cancer. Can malondialdehyde and catalase be markers of colorectal cancer advancement? *Biomolecules*. (2019) 9:637. doi: 10.3390/biom9060637

157. Martins BAA, de Bulhões GF, Cavalcanti IN, Martins MM, De Oliveira PG, Martins AMA. Biomarkers in colorectal cancer: the role of translational proteomics research. *Front Oncol*. (2019) 9:1284. doi: 10.3389/fonc.2019.01284

158. Kuniyasu H, Yano S, Sasaki T, Shimbo K, Eto S, et al. Cancer usurps skeletal muscle as an energy reservoir. *Cancer Res*. (2014) 74:330–40. doi: 10.1158/0008-5472.CAN-13-1052

159. Sugihara K, Sugiyama D, Byrne J, Wolf DP, Lowitz KP, Kobayashi Y, et al. Trophoblast cell activation by trophinin ligation is implicated in human embryo implantation. *Proc Natl Acad Sci USA*. (2007) 104:3799–804. doi: 10.1073/pnas.0611516104

160. Hatakeyama S, Ohyama C, Minagawa S, Inoue T, Kakinuma H, Ayan R, et al. Functional correlation of trophinin expression with the malignancy of testicular germ cell tumor. *Cancer Res*. (2004) 64:4257–62. doi: 10.1158/0008-5472.CAN-04-0732

161. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA*. (2006) 103:2257–61. doi: 10.1073/pnas.0510565103

162. Tili E, Michaille J-J, Wernicke D, Alder H, Costinean S, Volinia S, et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. *Proc Natl Acad Sci USA*. (2011) 108:4908–13. doi: 10.1073/pnas.110795108

163. Shibuya H, Inuma H, Shimada R, Horisuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. *Oncology*. (2010) 79:313–20. doi: 10.1159/000323283

164. Zhu P, Liu L, Mu W, Gu G, Lin X, Cai L, et al. Influence and mechanism of miR-99a suppressing development of colorectal cancer (CRC) with diabetes mellitus (DM). *Onco Targets Ther*. (2019) 12:10311–21. doi: 10.2147/OTT.S190998

165. Radia A-M, Yaser A-M, Ma X, Zhang J, Yang C, Dong Q, et al. Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. *Int J Mol Sci*. (2013) 14:7959–78. doi: 10.3390/ijms14047959

166. Gnanasekar M, Thirungannam S, Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. *Int J Oncol*. (2009) 34:425–31. doi: 10.3892/ijo.2009.715

167. Li R, Song Y, Zhou L, Li W, Zhu X. Downregulation of RAGE inhibits cell proliferation and induces apoptosis via regulation of PI3K/akt pathway in cervical squamous cell carcinoma. *Onco Targets Ther*. (2020) 13:2385–97. doi: 10.2147/OTT.S240378

168. Li Y, Wang J, Zhong S, Li J, Du W. Scutellarein inhibits the development of colon cancer via CDC4-mediated RAGE ubiquitination. *Int J Mol Med*. (2020) 45:1059–72. doi: 10.3892/ijmm.2020.4496

169. Zhang X, Wei L, Wang J, Qin Z, Wang J, Lu Y, et al. Suppression colitis and colitis-associated colon cancer by anti-S100a9 antibody in mice. *Front Immunol*. (2017) 8:1774. doi: 10.3389/fimmu.2017.01774

170. Billoud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. *Am J Gastroenterol*. (2011) 106:874–84. doi: 10.1038/ajg.2011.60

171. Plevy SE, Taragan SR. Future therapeutic approaches for inflammatory bowel diseases. *Gastroenterology*. (2011) 140:1838–46. doi: 10.1053/j.gastro.2011.02.014
185. Tagliazzucchi D, Martini S, Conte A. Protocatechuic and 3, 4-dihydroxyphenylacetic acids inhibit protein glycation by binding lysine through a metal-catalyzed oxidative mechanism. *J Agric Food Chem.* (2019) 67:7821–31. doi: 10.1021/acs.jafc.9b02357

186. Crasci L, Lauro MR, Puglisi G, Panico A. Natural antioxidant polyphenols on inflammation management: anti-glycation activity vs metalloproteinases inhibition. *Crit Rev Food Sci Nutr.* (2018) 58:893–904. doi: 10.1080/10408398.2016.1229657

187. Wei Z, Huang Q. Adverse health consequences of dietary advanced glycation end products (AGEs) and inhibitory effects of natural ingredients on ages. *Biomed J Sci Tech Res.* (2017) 1:1386–90. doi: 10.26717/BJSTR.2017.01.000443

188. Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. *Br J Pharmacol.* (2012) 166:2212–27. doi: 10.1111/j.1476-5381.2012.01910.x

189. Arabiyat S, Kasabri V, Al-Hiari Y, Al-Masri I, Alalawi S, Bustanji Y. Dual glycation-inflammation modulation, DPP-IV and pancreatic lipase inhibitory potentials and antiproliferative activity of novel fluoroquinolones. *Asian Pacif J Cancer Prev.* (2019) 20:2503–14. doi: 10.31557/APCJP.2019.20.8.2503

190. Brown DG, Borresen EC, Brown RJ, Ryan EP. Heat-stabilized rice bran activities of Carpobrotus edulis extracts. *Biomed Pharmacother.* (2016) 84:1496–503. doi: 10.1016/j.biopha.2016.11.046

191. Zhang L, Gao H-Y, Baba M, Okada Y, Chen A. Insulin promotes progression of colorectal cancer by upregulation of ACAT1. *Lipids Health Dis.* (2018) 17:1–7. doi: 10.1186/s12944-018-0773-x

192. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev.* (2003) 12:412–8.

193. Farahani H, Mahmoudi T, Asadi A, Nobakht H, Dabiri R, Hamta A. Insulin resistance and colorectal cancer risk: the role of elevated plasma resistin levels. *J Gastrointest Cancer.* (2019) 51:478–83. doi: 10.1007/s12029-019-00260-7

194. Chang C, Ulrich CM. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. *Diabetologia.* (2003) 46:595–607. doi: 10.1007/s00125-003-1109-5

195. Komminou D, Ayonote A, Richie Jr JF, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. *Exp Biol Med.* (2003) 228:396–405. doi: 10.1177/153537020322800410

196. Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients. *Med Hypotheses.* (2005) 64:1208–10. doi: 10.1016/j.mehy.2005.01.015

197. Schmidt AM, Du Yan S, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. *J Clin Invest.* (2001) 108:949–55. doi: 10.1172/JCI200114002

198. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. *Curr Mol Med.* (2007) 7:777–89. doi: 10.2174/156652407783220697

199. Chen J, Pitmon E, Wang K. Microbiome, inflammation and colorectal cancer. *Semin Immunol.* (2017) 32:43–53. doi: 10.1016/j.smim.2017.09.006

200. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. *Trends Mol Med.* (2002) 8:110–6. doi: 10.1016/S1471-4914(01)02194-3

201. Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. *J Vis Exp.* (2012) 3678. doi: 10.3791/3678

202. Yanar K, Aydin S, Çakatay U, Mengi M, Buyukpinarbaşili N, Atukeren P, et al. Protein and DNA oxidation in different anatomic regions of rat brain in a mimetic ageing model. *Basic Clin Pharmacol Toxicol.* (2011) 109:423–33. doi: 10.1111/j.1742-7843.2011.00756.x

203. Cai Z, Yan L-J. Protein oxidative modifications: beneficial roles in disease and health. *J Biochem Pharmacol Res.* (2013) 1:1–5–26.

204. Thornalley P. Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. *Biochem Soc Trans.* (2003) 31:(Pt 6):1372–7. doi: 10.1042/bst031372

205. Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, Belkaid Y, et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. *Science.* (2014) 343:1249288. doi: 10.1126/science.1249288

206. Ohkusa T, Koido S. Intestinal microbiota and ulcerative colitis. *J Infect.* (2015) 76:781–8. doi: 10.1016/j.jinf.2015.07.010

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Azizian-Farsani, Abedpoor, Hasan Sheikhha, Gure, Nasr-Esfahani and Ghaderi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.